细胞衰老在非酒精性脂肪性肝病中的作用与机制

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是一组连续疾病谱,受累人群数量逐年增长。目前除减重外,NAFLD缺乏有效的治疗方法。脂肪变性及肝纤维化是NAFLD疾病组的主要病理表现,靶向阻断病理生理进展是一种理想的治疗手段。近年来研究发现,细胞衰老在促进肝细胞脂肪变性、炎症及肝纤维化上发挥一定作用,这意味着药物治疗有了新的靶标。本文就细胞衰老在NAFLD中的作用与机制进行综述,旨在为NAFLD的诊治提供新思路。

关键词: 细胞衰老, 血栓调节蛋白, 脂肪变性, 肝纤维化, 非酒精性脂肪性肝病

董琳菲, 王艳. 细胞衰老在非酒精性脂肪性肝病中的作用与机制[J]. 肝脏, 2024, 29(2): 149-151.

参考文献

[1] Lucas V, Cavadas C, Aveleira CA. Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies[J]. Pharmacol Rev, 2023, 75(4): 675-713.
[2] Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing[J]. Nat Rev. Drug Discovery, 2017, 16(10): 718-735.
[3] Papatheodoridi AM, Chrysavgis L, Koutsilieris M, et al. The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis[J]. Hepatology, 2020, 71(1): 363-374.
[4] van Deursen JM. The role of senescent cells in ageing[J]. Nature, 2014, 509(7501): 439-446.
[5] Minamino T, Orimo M, Shimizu I, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance[J]. Nat Med, 2009, 15(9): 1082-1087.
[6] Aravinthan A, Scarpini C, Tachtatzis P, et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease[J]. J Hepatol, 2013, 58(3):549-556.
[7] Aravinthan A, Shannon N, Heaney J, et al. The senescent hepatocyte gene signature in chronic liver disease[J]. Exp Gerontol, 2014, 60: 37-45.
[8] Ogrodnik M, Miwa S, Tchkonia T, et al. Cellular senescence drives age-dependent hepatic steatosis[J]. Nat Commun, 2017, 8: 15691.
[9] Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2013, 145(5): 1076-1087.
[10] Hernández-Alvarez MI, Sebastián D, Vives S, et al. Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease[J]. Cell, 2019, 177(4): 881-895.e17.
[11] 孙宇. 细胞衰老的病理生理学意义和新型抗衰老药物的发展前景[J]. 生理学报, 2023, 75(6): 847-863.
[12] Duan JL, Liu JJ, Ruan B, et al. Age-related liver endothelial zonation triggers steatohepatitis by inactivating pericentral endothelium-derived C-kit[J]. Nat Aging, 2023, 3(3): 258-274.
[13] Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease[J]. Journal of Hepatology, 2019, 70(6): 1278-1291.
[14] Wan Y, Li X, Slevin E, et al. Endothelial dysfunction in pathological processes of chronic liver disease during aging[J]. FASEB J, 2022, 36(1): e22125.
[15] Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis[J]. Cell, 2008, 134(4): 657-667.
[16] Yu H, Jiang X, Dong F, et al. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway[J]. Exp Cell Res, 2021, 405(2): 112689.
[17] 胡昌龙, 王琳. 肝脏血管微环境与肝脏损伤[J]. 生命的化学, 2023, 43(7): 1092-1099.
[18] Jin H, Lian N, Zhang F, 等. Activation of PPARγ/P53 signaling is required for curcumin to induce hepatic stellate cell senescence[J]. Cell Death Dis, 2016, 7(4): e2189.
[19] Serna-Salas SA, Arroyave-Ospina JC, Zhang M, et al. α-1 Adrenergic receptor antagonist doxazosin reverses hepatic stellate cells activation via induction of senescence[J]. Mech Ageing Dev, 2022, 201: 111617.
[20] Pan CC, Maeso-Díaz R, Lewis TR, et al. Antagonizing the irreversible thrombomodulin-initiated proteolytic signaling alleviates age-related liver fibrosis via senescent cell killing[J]. Cell Res, 2023, 33(7): 516-532.
[21] Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs[J]. Aging Cell, 2015, 14(4): 644-658.
[22] Nambiar A, Kellogg D, Justice J, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability[J]. EBioMedicine, 2023, 90: 104481.